--- title: "Neoadjuvant Pediatric Leukemia AALL1821 | Sutter Health" description: "A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse." url: "https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-pediatric-leukemia-aall1821-1049141818" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Clinical trials](https://www.sutterhealth.org/research/clinical-trials) / 4. Neoadjuvant Pediatric Leukemia AALL1821 # Neoadjuvant Pediatric Leukemia AALL1821 **Status:** Open to Enrollment [Email us to enroll](https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-pediatric-leukemia-aall1821-1049141818#enroll) #### Study details View study details on [www.clinicaltrials.gov](https://www.clinicaltrials.gov/ct2/show/NCT04546399?cond=04546399&draw=2&rank=1). #### Locations - Sacramento #### Clinical trial FAQs Information for patients and study volunteers, including [frequently asked questions](https://www.sutterhealth.org/research/faqs). This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blinatumomab searches for and attaches itself to the cancer cell. Once attached, an immune response occurs which may kill the cancer cell. Nivolumab is a medicine that may boost a patient's immune system. Giving nivolumab in combination with blinatumomab may cause the cancer to stop growing for a period of time, and for some patients, it may lessen the symptoms, such as pain, that are caused by the cancer. ![Sandra K Baril, M.D.](https://dyn.mktgcdn.com/p/LeDczJiBVc-OKMwdWQTzaO-WX-HJKEXWeWf47e1fMY4/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100) Sandra K Baril, M.D. Principal investigator [View profile](https://www.sutterhealth.org/research/investigators/sandra-k-baril-md-2016036488) ## Sub-Investigators [Saunders C Hsu, M.D., MPH](https://www.sutterhealth.org/research/investigators/saunders-c-hsu-md-mph-1049681145) , [Rachel Bito, M.D.](https://www.sutterhealth.org/research/investigators/rachel-bito-md-2070392186) , [Janice K Ryu, M.D.](https://www.sutterhealth.org/research/investigators/janice-k-ryu-md-2016036552) ## Email us to enroll - [Email Sacramento](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Neoadjuvant%20Pediatric%20Leukemia%20AALL1821%20in%20Sacramento&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.) ## Related clinical trials [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) - Clinical trial ### [Acute Myeloid Leukemia Dental Wipes COG ACCL2531](https://www.sutterhealth.org/research/clinical-trials/acute-myeloid-leukemia-dental-wipes-cog-accl2531-2099128841) A Randomized Double-Blinded Trial of Xylitol Dental Wipes for the Prophylaxis of Bloodstream Infections From Oral Organisms in Pediatric Patients With Acute Myeloid Leukemia **Status:** Open to Enrollment - Clinical trial ### [Recurrent or Refractory B Lymphoblastic Lymphoma AALL1621](https://www.sutterhealth.org/research/clinical-trials/recurrent-or-refractory-b-lymphoblastic-lymphoma-aall1621-2070392315) A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL) **Status:** Open to Enrollment - Clinical trial ### [Pediatric B-Lymphoblastic Leukemia COG AALL1732](https://www.sutterhealth.org/research/clinical-trials/cogaall1732-1049141808) A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLyLy **Status:** Open to Enrollment - Clinical trial ### [Pediatric Cancer Project Every Child APEC14B1](https://www.sutterhealth.org/research/clinical-trials/pediatric-cancer-project-every-child-apec14b1-1049141838) The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study **Status:** Open to Enrollment - Clinical trial ### [Pediatric Long Term Follow Up ALTE05N1](https://www.sutterhealth.org/research/clinical-trials/cogalte05n1-1049141846) Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies **Status:** Open to Enrollment [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-pediatric-leukemia-aall1821-1049141818#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Clinical trials","item":"https://www.sutterhealth.org/research/clinical-trials"},{"@type":"ListItem","position":4,"name":"Neoadjuvant Pediatric Leukemia AALL1821"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalWebPage","@id":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-pediatric-leukemia-aall1821-1049141818#medicalwebpage","name":"Neoadjuvant Pediatric Leukemia AALL1821","description":"A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to \u003c 31 Years Old With First Relapse.","url":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-pediatric-leukemia-aall1821-1049141818","inLanguage":"en-US","dateModified":"2026-08-10","publisher":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"},"medicalAudience":{"@type":"MedicalAudience","audienceType":"Patient"},"mainEntity":{"@id":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-pediatric-leukemia-aall1821-1049141818#medicaltrial"},"breadcrumb":{"@id":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-pediatric-leukemia-aall1821-1049141818#breadcrumblist"},"mentions":[{"@type":"Person","name":"Sandra K Baril, M.D.","url":"https://www.sutterhealth.org/research/investigators/sandra-k-baril-md-2016036488","jobTitle":"Principal Investigator","affiliation":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"}}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalTrial","@id":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-pediatric-leukemia-aall1821-1049141818#medicaltrial","name":"Neoadjuvant Pediatric Leukemia AALL1821","alternateName":"A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to \u003c 31 Years Old With First Relapse.","url":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-pediatric-leukemia-aall1821-1049141818","description":"This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blinatumomab searches for and attaches itself to the cancer cell. Once attached, an immune response occurs which may kill the cancer cell. Nivolumab is a medicine that may boost a patient's immune system. Giving nivolumab in combination with blinatumomab may cause the cancer to stop growing for a period of time, and for some patients, it may lessen the symptoms, such as pain, that are caused by the cancer.","identifier":"NCT04546399","code":{"@type":"MedicalCode","codeValue":"NCT04546399","codingSystem":"ClinicalTrials.gov"},"sameAs":"https://www.clinicaltrials.gov/ct2/show/NCT04546399?cond=04546399&draw=2&rank=1","status":"https://schema.org/Recruiting","healthCondition":[{"@type":"MedicalCondition","name":"Leukemia, Pediatric"}],"studyLocation":[{"@type":"AdministrativeArea","name":"Sacramento"}]} ```